ABVC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ABVC Biopharma is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock lacks a bullish technical setup, has no recent news catalyst, shows extremely weak latest-quarter fundamentals, and does not have supportive proprietary trading signals. Given the user's impatience and preference not to wait for an ideal entry, the clearest view is to avoid buying this name now.
The chart setup is weak. MACD histogram is slightly negative and still below zero, RSI at 51.84 is neutral, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which indicates the stock remains in a downtrend. Price at 1.1146 is only slightly above pivot 1.073 and below resistance R1 at 1.126, so upside is limited unless it breaks through resistance decisively. The pattern-based forecast also points lower over the next day, week, and month.
No news was reported in the recent week. The only modest positive factor is that the stock is trading slightly above the previous close and near the pivot area, but there is no event-driven catalyst or confirmed proprietary buy signal to build on.
There is also no recent news, no recent congress trading data, no meaningful insider accumulation, and hedge funds are neutral. The stock trend projection is also negative.
In 2025/Q4, ABVC reported a severe deterioration in fundamentals. Revenue fell 100.00% YoY to 0, net income declined to -3,562,944, EPS dropped to -0.14, and gross margin fell to 0. For a long-term beginner investor, this does not support a buy decision because there is no visible growth trend in the latest quarter.
No analyst rating or price target change data was provided, so there is no evidence of a favorable Wall Street revision trend. Based on the available information, Wall Street pros would likely lean negative or neutral: the cons dominate due to collapsing revenue, negative earnings, lack of catalysts, and weak technical structure. The pros case is thin and mostly limited to the absence of heavy insider or hedge fund selling.
